stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Return on equity
Tango Therapeutics, Inc.'s return on equity over the twelve months to 30 June 2026 was −21.3%, up 15.9 percentage points from fiscal 2025 (−37.2%). Over the past ten years it has ranged from −57.6% (fiscal 2024) to −20.5% (fiscal 2020); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −37.2% | 20.35 |
| FY2024 | −57.6% | (17.09) |
| FY2023 | −40.5% | (4.08) |
| FY2022 | −36.4% | (6.03) |
| FY2021 | −30.4% | (9.88) |
| FY2020 | −20.5% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| IRON Disc Medicine, Inc. compare | −39.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −43.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement